Zobrazeno 1 - 10
of 36
pro vyhledávání: '"William R. Wilson"'
Autor:
Simon Rule, William R. Wilson, Richard Lush, Deborah Turner, Andrew P. Haynes, Laura Clifton-Hadley, Mark Bishton, Andrew McMillan, Russell Patmore
Publikováno v:
British journal of haematologyReferences. 190(4)
We present a long-term follow-up of the UK chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced, symptomatic follicular lymphoma (FL). This trial was the first to prospecti
Autor:
Reidar Grénman, John Nemunaitis, Mark Zaidi, William R. Wilson, Courtney R. H. Lynch, Trevor D. McKee, Cho R. Hong, Peter Tsai, Charles P. Hart, Dennis Kee, Purvi M. Kakadia, John M. Chaplin, Tet Woo Lee, Bradly G. Wouters, Stephen M. F. Jamieson, Arthur Liu, Nicholas P. McIvor, Francis W. Hunter, Shadia I. Jalal, Cristin G. Print, Nicholas Knowlton, E. Gabriela Chiorean, Nooriyah Poonawala-Lohani, Way W. Wong, Kevin O. Hicks, Dan Li, Laura Caporiccio, Neil Senzer, Avik Shome, Michael A. Curran, Andrew Macann, Pratha Budhani, Maria Kondratyev, Stefan K. Bohlander, Sehrish Butt
Publikováno v:
JCI Insight. 3(16)
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits
Autor:
William R. Wilson, Naval Daver, Peter F. Thall, Hagop M. Kantarjian, Tapan M. Kadia, Naveen Pemmaraju, Jennie Feliu, Andrew Coveler, John Gutheil, Sergej Konoplev, Caimiao Wei, Carlos E. Bueso-Ramos, Stefan Faderl, Hongbo Lu, Cecilia Arana Yi, Hoang Q. Nguyen, Juliana Benito, Farhad Ravandi, Jorge E. Cortes, Deborah A. Thomas, Yongchuan Gu, Michael Andreeff, Teresa J. Melink, Marina Konopleva, Elihu H. Estey, Elias Jabbour, Steven M. Kornblau, Gautam Borthakur
Publikováno v:
Haematologica. 100:927-934
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-1
Publikováno v:
Journal of Shoulder and Elbow Surgery. 22:856-861
Purpose Anterior shoulder anatomy is as complex and variable as its descriptive terminology. A detailed understanding of normal anatomic variability is critical to accurate performance, description, and evaluation of the procedures involving the rota
Autor:
Mark D. Pegram, Danny Rischin, John Gutheil, William A. Denny, Michael B. Jameson, Adam V. Patterson, William R. Wilson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 65:791-801
PR-104 is a "pre-prodrug" designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted to establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT),
Autor:
Michael B. Jameson, William R. Wilson, Yongchuan Gu, Ramesh K. Ramanathan, N. Simon Tchekmedyian, Mark J. McKeage, Joseph G. Rajendran, Teresa J. Melink
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 496 (2012)
BMC Cancer
BMC Cancer
Background The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced solid tumours. Methods PR-104 w
Autor:
Ernest C. Madu, William R. Wilson, Theodore D. Fraker, Mark W. Burket, Gary M. Ansel, Daniel Kosinski
Publikováno v:
Angiology. 45:809-816
The authors report a case of early peripartum myocardial infarction resulting from spontaneous dissection of the left anterior descending coronary artery and right coronary artery in a twenty-four-year-old woman. This is the first report of double-ve
Autor:
Michael B. Jameson, William R. Wilson, Teresa J. Melink, Yongchuan Gu, Andrew G. Hill, Mark J. McKeage, Karen Amies
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 432 (2011)
BMC Cancer
BMC Cancer
Background The phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is metabolised to hydroxylamine (PR-104H) and amine (PR-104M) DNA crosslinking agents by one-electron reductases in hypoxic cel
Autor:
William R. Wilson, William D. Carter, Teresa J. Melink, Mary F. Mulcahy, Chao Jung Tsao, John Gutheil, E. Gabriela Chiorean, Stephen L. Chan, Ghassan K. Abou-Alfa, Randall F. Holcombe, Chia Chi Lin, Kashyap Patel
Publikováno v:
Cancer chemotherapy and pharmacology. 68(2)
PR-104 is activated by reductases under hypoxia or by aldo-keto reductase 1C3 (AKR1C3) to form cytotoxic nitrogen mustards. Hepatocellular carcinoma (HCC) displays extensive hypoxia and expresses AKR1C3. This study evaluated the safety and efficacy o
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 337(3)
PR-104, the phosphate ester of a dinitrobenzamide mustard [PR-104A; 2-((2-bromoethyl)-2-{[(2-hydroxyethyl) amino] carbonyl}-4,6-dinitroanilino)ethyl methanesulfonate], is currently in clinical trial as a hypoxia- and aldo-keto reductase 1C3 (AKR1C3)-